A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adults With Hodgkin and Non-Hodgkin Lymphoma

Model scores of the 29,894 trials active now.

Model score 22% for any early termination, 4% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 29% of the time (655 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2025-12-03. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: celllymphomahodgkinfailurestandard
  Phrases that lowered it: participantsparticipantefficacypharmacokineticsclinical
• Accepts healthy volunteers: No (raises risk) · Who can join
• Sponsor's past termination rate: 10.1% (raises risk) · Sponsor's track record
• Phase: 1/2 (raises risk) · Design
• Drug's FAERS reports with a death: 28.7% (raises risk) · Drug's FDA history
• Has a data monitoring committee: Yes (raises risk) · Design
• Disease area, cancer: Yes (raises risk) · Disease area
• Minimum age: not given (raises risk) · Who can join
• Trials the sponsor started in the prior 2 years: 75 (lowers risk) · Sponsor's track record
• Sponsor's past trials: 835 (raises risk) · Sponsor's track record
• Design: sequential (raises risk) · Design
• Sponsor type: industry (lowers risk) · Sponsor's track record
• Keywords listed: 13 (raises risk) · Design
• Number of arms: 1 (raises risk) · Design
• Primary purpose: treatment (raises risk) · Design
• Collaborators: 0 (raises risk) · Design
• Maximum age: 30 (lowers risk) · Who can join
• Blinding: none (raises risk) · Design
• Drug's FAERS reports before start: 67877 (lowers risk) · Drug's FDA history

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Tislelizumab in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma NCT04318080 · started 2020 · scored riskier than 19% of active trials completed
• A Study to Evaluate the Safety, Tolerability, and Efficacy of Relatlimab in Relapsed or Refractory B-Cell Malignancies NCT02061761 · started 2014 · scored riskier than 38% of active trials completed
• A Study of Nivolumab Plus Brentuximab Vedotin in Patients Between 5 and 30 Years Old, With Hodgkin's Lymphoma (cHL), Relapsed or Refractory From First Line Treatment NCT02927769 · started 2017 · scored riskier than 67% of active trials completed
• Tislelizumab Monotherapy Versus Salvage Chemotherapy for Relapsed/Refractory Classical Hodgkin Lymphoma NCT04486391 · started 2020 · scored riskier than 18% of active trials terminated
• Safety and Preliminary Efficacy Assessment of AZD7789 in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma NCT05216835 · started 2022 · scored riskier than 40% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.